BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19728029)

  • 1. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.
    Björklund E; Gruber A; Mazur J; Mårtensson A; Hansson M; Porwit A
    Int J Hematol; 2009 Oct; 90(3):292-302. PubMed ID: 19728029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
    Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.
    Macedo A; Orfao A; Ciudad J; Gonzalez M; Vidriales B; Lopez-Berges MC; Martínez A; Landolfi C; Cañizo C; San Miguel JF
    Leukemia; 1995 Nov; 9(11):1896-901. PubMed ID: 7475281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
    Hsu FC; Hudson C; Wilson ER; Pardo LM; Singleton TP; Xu D; Zehentner BK; Hitzler J; Berman J; Wells DA; Loken MR; Brodersen LE
    Cytometry B Clin Cytom; 2023 Jul; 104(4):311-318. PubMed ID: 37015883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
    Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).
    Nagler A; Condiotti R; Rabinowitz R; Schlesinger M; Nguyen M; Terstappen LW
    Med Oncol; 1999 Sep; 16(3):177-87. PubMed ID: 10523797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood.
    Fritsch G; Stimpfl M; Kurz M; Printz D; Buchinger P; Fischmeister G; Hoecker P; Gadner H
    Bone Marrow Transplant; 1996 Feb; 17(2):169-78. PubMed ID: 8640162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric analysis of hemetopoietic progenitor cells in peripheral blood stem cell harvest from patients with CD34 positive acute leukemia.
    Miyazaki T; Matsuda I; Oguri M; Amaya H; Kiyosaki M; Hamada A; Tamaki S; Tashiro E; Kudo Y; Taniguchi O; Nakamura T; Tomoyasu S
    J Immunol Methods; 2001 Jan; 247(1-2):9-15. PubMed ID: 11150532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.